Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.69 |
| ▸ | MRGPRX4 | Q96LA9 | 14/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.63 |
| ▸ | RELA | Q04206 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25203039 | 0.96 | NR4A2 (0.71) | NR4A2MRGPRX4 | |
| SCHEMBL30391969 | 0.96 | NR4A2 (0.71) | NR4A2MRGPRX4 | |
| SCHEMBL4684138 | 0.89 | MRGPRX4 (0.70) | NR4A2MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL4406160 | 0.89 | NR4A2 (0.87) | NR4A2MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL30392119 | 0.86 | SMPD1 (0.74) | NR4A2MRGPRX4SMN1; SMN2RAB9A | |
| SCHEMBL25214512 | 0.86 | SMPD1 (0.74) | NR4A2MRGPRX4SMN1; SMN2RAB9A | |
| SCHEMBL851377 | 0.86 | MEN1 (0.68) | NR4A2MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL4138759 | 0.85 | NR4A2 (0.81) | NR4A2MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL9585749 | 0.84 | FFAR1 (0.60) | NR4A2MRGPRX4 | |
| SCHEMBL1122713 | 0.83 | NR4A2 (0.94) | NR4A2MRGPRX4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | NR4A2 3598/4885MRGPRX4 3064/4885TP53 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.